

Table S1. Patient exposure and baseline characteristics in rheumatoid arthritis patients treated with adalimumab (N = 15,152)

Parameter	
Exposure (patient-years)	24,810.4
>2 years of exposure (%)	16.5
>5 years of exposure (%)	10.9
Mean Age (years)	53.5
Female (%)	78.8
White (%)	86.5
Mean Disease duration* (years)	9.1
Concomitant† cs DMARDs‡ (%)	64.9
MTX (%)	55.7
Concomitant systemic steroids (%)	64.0

* Data available for N=15,002 only.

† Concomitant use at baseline.

‡ csDMARD: conventional synthetic disease-modifying antirheumatic drug; MTX: methotrexate.

Figure S1. Mean change from baseline in total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol serum concentrations after six months of adalimumab treatment in early rheumatoid arthritis patients. Cholesterol concentrations in SI units. * $P < 0.05$ for the comparison adalimumab-plus-methotrexate (dark-shaded bars) versus methotrexate-monotherapy (light-shaded bars).




Figure S2. Frequency of patients experiencing influenza-related adverse events with and without influenza vaccination. AE, adverse event.






Figure S3: Mean change from baseline in Apoprotein A-1 (A), cholesterol (B) and HDL (C) for each treatment group

A



B



C

